Product Pipeline

OriCell Therapeutics focuses on the unmet clinical needs for the treatment of liver cancer, ovarian cancer, gastric cancer, cervical cancer, and non-small cell lung cancer. It has developed several dozen pipelines for independently innovative cell drugs and monospecific/bispecific antibodies targeting solid tumors. Among them, six immune cell therapy products for tumors have been approved by the ethical committee of the hospital and entered the stage of exploratory clinical development. The Investigational New Drug (IND) application for four products has been initiated. The application materials for the first product will be submitted in the first quarter of 2022. The IND application for the other 3 products is currently underway.